Drug Approval | January 16, 2023
Granules India’s Gagillapur facility completes USFDA inspection
The company will respond to these observations within the stipulated time period.
The company will respond to these observations within the stipulated time period.
The hospital will have all the modern facilities like modular OT, state of the art medical equipment, labs, etc. It will have OPD and IPD services
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
Under the soon to be launched Heal in India initiative, India aims to provide its health infrastructure for patients abroad and make it a global hub for medical and value-based healthcare for patients from across the world
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs
The goal of Dozee’s partnership with BII is to improve access to healthcare across India and alleviate the workload of healthcare workers, reduce nurse burnout and fatigue in hospital wards
The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
Subscribe To Our Newsletter & Stay Updated
